ライフサイエンスコーパス: binge eating

1 own Obsessive Compulsive Scale (modified for binge eating).

2 lthy weight-control behaviors, and engage in binge eating.

3 K1521498, in obese individuals with moderate binge eating.

4 receptors (Sig-1Rs) blocked compulsive-like binge eating.

5 also be applicable to adolescent bulimia and binge eating.

6 nd the propensity to purge in the absence of binge eating.

7 tify quantitative trait loci associated with binge eating.

8 n more weight than do children not reporting binge eating.

9 nce that reward, over metabolic need, drives binge eating.

10 el pharmacological treatment for compulsive, binge eating.

11 ress-induced drug seeking, in stress-induced binge eating.

12 onal psychotherapy further reduced objective binge eating.

13 ing, unhealthy weight-control behaviors, and binge eating.

14 ction, may also be effective in ameliorating binge eating.

15 d disorders, eg, substance-use disorders and binge-eating.

16 and motivational processing of food, and in binge eating, a behaviour strongly linked to obesity.

17 apist-assisted (33.3%) conditions had higher binge eating abstinence rates than the self-help (17.9%)

18 ment for binge eating disorder led to higher binge eating abstinence rates, greater reductions in bin

19 PC1 ('binge-eating'), accounting for 38% of variation, capture

20 However, how binge eating affects children's food intake at meals is

21 Binge eating afflicts approximately 5% of US adults, tho

22 antly more effective than BWL in eliminating binge eating after 2 years.

23 Obese subjects with binge eating also have impaired discrimination of subjec

24 Assessments of binge eating and associated eating disorder psychopathol

25 in the Arab region; and increasing rates of binge eating and bulimia nervosa in Hispanic and Black A

26 treatment experienced greater improvement in binge eating and depression than did patients receiving

27 NAS DBS was found to reduce binge eating and increased c-Fos levels in this region.

28 uses evolved protective mechanisms including binge eating and increased metabolic efficiency and fat

29 Secondary endpoints related to binge eating and medical parameters, safety, and treatme

30 was to examine whether dieting would elicit binge eating and mood disturbance in individuals free of

31 petitive responses in psychopathology; e.g., binge eating and opiate or alcohol abuse, disorders in w

32 estigators fear that dieting may precipitate binge eating and other adverse behavioral consequences.

33 ore, results suggested that higher levels of binge eating and overeating in males at age 13 y likely

34 Furthermore, higher levels of binge eating and overeating may cause higher BMI in late

35 MI at age 7 y likely causes higher levels of binge eating and overeating, weight and shape concerns,

36 major significant genetic factor underlying binge eating and provide a behavioral paradigm for futur

37 choanalytic psychotherapy (N=34) had stopped binge eating and purging (odds ratio=13.40, 95% confiden

38 ychoanalytic psychotherapy group had stopped binge eating and purging (odds ratio=4.34, 95% CI=1.33-1

39 Thirteen female adolescents with binge eating and purging behaviors (i.e., bulimia nervos

40 purging distinguishes among individuals with binge eating and purging behaviors.

41 who responded with complete abstinence from binge eating and purging to cognitive behavioral therapy

42 vioral therapy with complete abstinence from binge eating and purging.

43 eating pathology, most engaged in recurrent binge eating and purging.

44 sdexamfetamine, SGAs, and topiramate reduced binge eating and related psychopathology, and lisdexamfe

45 Binge eating and substance dependence are disorders char

46 cing behavioral symptoms of bulimia nervosa (binge eating and vomiting).

47 ian visits, exhibited a greater reduction in binge eating and vomiting, and had a greater improvement

48 ically significant effects in the context of binge eating and weight regain prevention requires furth

49 ent of binge eating disorder, impacting both binge eating and weight.

50 are mainly vagally mediated functions, since binge-eating and vomiting produce intense stimulation of

51 The decrease in binge-eating and vomiting under ondansetron treatment wa

52 rimary outcome measures were abstinence from binge-eating and vomiting, as assessed by interview at e

53 isition in disorders involving both natural (binge eating) and artificial (methamphetamine) rewards,

54 ers (eg, pathological gambling and shopping, binge eating, and hypersexuality), punding (ie, abnormal

55 utative causal factor in chronic overeating, binge eating, and obesity.

56 contribute to the onset of extreme dieting, binge eating, and purging.

57 neural circuitry of restrictive food choice, binge eating, and the contribution of specific serotonin

58 body dissatisfaction, weight preoccupation, binge eating, and the use of compensatory behaviors) wer

59 amen/pallidal responses in obese people with binge eating are sensitive to altered mu-opioid function

60 ustify whether classification of obesity and binge eating as an addictive disorder is merited.

61 Binge eating as measured by the Eating Disorder Examinat

62 Overeating and binge eating assessed via questionnaire every 12 to 24 m

63 led condition also showed more reductions in binge eating at end of treatment and follow-up assessmen

64 than health education at reducing objective binge eating at the 12-mo follow-up (P < 0.05).

65 Binge eating (BE) is common in overweight and obese indi

66 We assessed the change in binge-eating (BE) behaviors measured as days per week (b

67 rette's syndrome, the obsessions of OCD, the binge eating behaviors of bulimia, and the self-starvati

68 n disordered eating and obesity, emphasizing binge eating, binge eating disorder and food addiction a

69 psychotherapy (IPT) has been shown to reduce binge eating but its long-term impact and time course on

70 order characterized by recurrent episodes of binge eating but without purging behaviors.

71 In fully adjusted models, binge eating, but not overeating, was associated with in

72 d-Fenfluramine reduced the frequency of binge eating by obese women with binge eating disorder.

73 After the standardized breakfast, binge-eating children reported a shorter satiety duratio

74 y a role in the greater weight gain found in binge-eating children.

75 tional properties of stimuli that elicit the binge eating commonly associated with obesity.

76 8 weeks), lisdexamfetamine responders (</=1 binge eating day per week for 4 consecutive weeks and CG

77 Change from baseline in binge eating days/week at weeks 11-12 (primary efficacy

78 eatment differences for change from baseline binge eating days/week at weeks 11-12 significantly favo

79 g/day) was superior to placebo in decreasing binge eating days/week from baseline and improving binge

80 derate to severe binge eating disorder (>/=3 binge-eating days per week for 14 days before open-label

81 mary outcome variable, time to relapse (>/=2 binge-eating days per week for 2 consecutive weeks and >

82 disorder criteria and had moderate to severe binge eating disorder (>/=3 binge-eating days per week f

83 were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]).

84 l survey, the average lifetime prevalence of binge eating disorder (BED) was 2%.

85 dexamfetamine dimesylate (LDX) vs placebo in binge eating disorder (BED) was evaluated in two multice

86 teen obese individuals seeking treatment for binge eating disorder (BED) were compared with 19 non-BE

87 subjects with (n = 30) and without (n = 30) binge eating disorder (BED) were compared with matched h

88 ents the criterion standard for treatment of binge eating disorder (BED), most individuals do not hav

89 IPT) is an effective specialty treatment for binge eating disorder (BED).

90 n phenotypes: pathological gambling (PG) and binge eating disorder (BED).

91 has documented efficacy for the treatment of binge eating disorder (BED).

92 ide the United States on the epidemiology of binge eating disorder (BED).

93 The Internet and Binge Eating Disorder (INTERBED) study is a prospective,

94 s among relatives with lifetime diagnoses of binge eating disorder (N=131), bulimia nervosa (N=17), a

95 N=4, 0.4%) met criteria for bulimia nervosa; binge eating disorder also was more common among white w

96 f 300 overweight or obese probands (150 with binge eating disorder and 150 with no lifetime eating di

97 A community sample of 162 women with binge eating disorder and 251 healthy and 107 psychiatri

98 d bulimia nervosa and more likely to exhibit binge eating disorder and eating disorder not otherwise

99 ating and obesity, emphasizing binge eating, binge eating disorder and food addiction as useful conce

100 sa and bulimia nervosa; and the inclusion of binge eating disorder as a formal diagnosis.

101 y of research also supports the inclusion of binge eating disorder as a formal diagnosis.

102 port for conceptualizing bulimia nervosa and binge eating disorder as discrete syndromes.

103 s to evaluate topiramate in the treatment of binge eating disorder associated with obesity.

104 ell tolerated in the short-term treatment of binge eating disorder associated with obesity.

105 sorder and 2.9% had partial or full-criteria binge eating disorder but no association with the outcom

106 This study assessed the stability of binge eating disorder in a community sample.

107 ce of anorexia nervosa, bulimia nervosa, and binge eating disorder in a geographically and economical

108 ciated with an increased risk for developing binge eating disorder in black women and in white women

109 Our findings support a distinct subtype of binge eating disorder in obesity with similarities in ri

110 Binge eating disorder is an addiction-like disorder char

111 Binge eating disorder is associated with obesity.

112 These findings suggest that binge eating disorder is at least as chronic as the well

113 led group cognitive-behavioral treatment for binge eating disorder led to higher binge eating abstine

114 White subjects with binge eating disorder reported significantly higher rate

115 Binge eating disorder represents a public health problem

116 n the anticipation of rewards, subjects with binge eating disorder show greater risk-taking, similar

117 ere significantly higher in white women with binge eating disorder than in matched psychiatric compar

118 ere significantly higher in black women with binge eating disorder than in psychiatric comparison sub

119 was to compare three types of treatment for binge eating disorder to determine the relative efficacy

120 The mean lifetime duration of binge eating disorder was 14.4 years (SD=13.9), signific

121 Neither depression nor binge eating disorder was consistently associated with d

122 A total of 259 adults diagnosed with binge eating disorder were randomly assigned to 20 weeks

123 icipants (N=304) who met DSM-IV criteria for binge eating disorder were randomly assigned to 24 weeks

124 Thirty-four outpatients with DSM-IV binge eating disorder were randomly assigned to receive

125 Anorexia nervosa and binge eating disorder were relatively uncommon.

126 l, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index >/

127 ies reporting pharmacological treatments for binge eating disorder, advances in treatment for adults

128 ries are: anorexia nervosa, bulimia nervosa, binge eating disorder, and eating disorder not otherwise

129 or attention deficit hyperactivity disorder, binge eating disorder, cocaine addiction, obesity, and t

130 trol disorders, including gambling disorder, binge eating disorder, compulsive sexual behaviour, and

131 sibutramine is effective in the treatment of binge eating disorder, impacting both binge eating and w

132 gnosis of anorexia nervosa, bulimia nervosa, binge eating disorder, or eating disorder not otherwise

133 In black women with binge eating disorder, rates of sexual abuse, physical a

134 pled with a lack of control over eating, and binge eating disorder, the Diagnostic and Statistical Ma

135 tablished treatments for bulimia nervosa and binge eating disorder, with stepped-care approaches show

136 stigation towards pharmacologically treating binge eating disorder.

137 trial to test the efficacy of sibutramine in binge eating disorder.

138 e in risk is specific for the development of binge eating disorder.

139 al abuse and discrimination) in the risk for binge eating disorder.

140 ctive and well tolerated in the treatment of binge eating disorder.

141 e efficacy of sertraline in the treatment of binge eating disorder.

142 jor eating disorders and a related syndrome, Binge Eating Disorder.

143 se female patients meeting full criteria for binge eating disorder.

144 ppressant d-fenfluramine in the treatment of binge eating disorder.

145 requency of binge eating by obese women with binge eating disorder.

146 rgery patients-in particular, depression and binge eating disorder.

147 Binge-eating disorder (BED) is characterized by recurrin

148 Binge-eating disorder (BED), a public health problem ass

149 l or food, in alcohol use disorders (AUD) or binge-eating disorder (BED), suggest a disturbance in ex

150 Binge-eating disorder (BED)-a syndrome that only recentl

151 Women with binge-eating disorder (BED; n = 38) and age- and weight-

152 ade for atypical eating disorders except for binge-eating disorder (cognitive behavioural therapy was

153 Binge-eating disorder aggregated strongly in families in

154 5 and 5 y of follow-up, 134 individuals with binge-eating disorder and 134 individuals with no histor

155 o assess longitudinally the relation between binge-eating disorder and components of the metabolic sy

156 The best treatment options for binge-eating disorder are unclear.

157 Women with binge-eating disorder before and during pregnancy had hi

158 a before and during pregnancy and those with binge-eating disorder before pregnancy exhibit dietary p

159 Eligible adults met DSM-IV-R binge-eating disorder criteria and had moderate to sever

160 up intakes of women with bulimia nervosa and binge-eating disorder during pregnancy and compared thes

161 Women with incident binge-eating disorder during pregnancy had higher intake

162 comparison of individuals with and without a binge-eating disorder in analyses adjusted for age, sex,

163 Binge-eating disorder is a familial disorder caused in p

164 Binge-eating disorder is a newly described eating disord

165 Binge-eating disorder is characterized by excessive, unc

166 Binge-eating disorder may confer a risk of components of

167 Binge-eating disorder may represent a risk factor for th

168 es of anorexia nervosa, bulimia nervosa, and binge-eating disorder were 0.3%, 0.9%, and 1.6%, respect

169 -five outpatients with a DSM-IV diagnosis of binge-eating disorder were randomly assigned to receive

170 o time did any participant meet criteria for binge-eating disorder.

171 ns of anorexia nervosa, bulimia nervosa, and binge-eating disorder.

172 ns of anorexia nervosa, bulimia nervosa, and binge-eating disorder.

173 t outcome measures in the acute treatment of binge-eating disorder.

174 efficacy of fluvoxamine in the treatment of binge-eating disorder.

175 f efficacy in adults with moderate to severe binge-eating disorder.

176 and topiramate reduced weight in adults with binge-eating disorder.

177 he characteristic symptomatology observed in binge-eating disorder.

178 as a potential pharmacological treatment for binge-eating disorder.

179 ncts to psychotherapy for bulimia nervosa or binge-eating disorder; in the case of anorexia nervosa,

180 derstanding of the etiology and treatment of binge eating disorders.

181 ty of children with and without a history of binge eating during buffet meals.

182 ference in the number of days with objective binge eating episodes (OBEs) during the previous 28 days

183 Within the patient group, the frequency of binge eating episodes during the 4 weeks prior to the st

184 frequency of vomiting episodes, frequency of binge eating episodes, Clinical Global Impression severi

185 y were categorized into those reporting past binge-eating episodes (n = 10) and those reporting no su

186 e primary outcome measures were frequency of binge eating, expressed as log ([binges/week]+1), and Cl

187 of the variance in eating disorder symptoms: binge eating, fear of fatness/compensatory behaviors, an

188 ting abstinence rates, greater reductions in binge eating frequency, and lower attrition compared to

189 ramate also increased abstinence and reduced binge-eating frequency and related psychopathology.

190 tion among patients sustaining recovery from binge eating from posttreatment to 1-year follow-up.

191 Children who report episodes of binge eating gain more weight than do children not repor

192 ic capacity, perhaps resulting from repeated binge eating, gives rise to delayed gastric emptying and

193 After the overnight fast, children in the binge-eating group consumed more energy [x (+/-SD): 1748

194 min; P = 0.03) than did children in the non-binge-eating group.

195 the anticipation of losses, obesity without binge eating had a similar pattern to other substance-us

196 We assessed binge eating in closely related C57BL/6 mouse substrains

197 Cyfip2 as a major genetic factor underlying binge eating in heterozygous knockout mice on a C57BL/6N

198 ve both resulted in short-term reductions in binge eating in obese patients with BED.

199 pin-releasing factor (CRF) in stress-induced binge eating in our model.

200 e of CRF receptors in BNST in stress-induced binge eating in our rat model.

201 n-active antidepressant medications decrease binge eating in patients with bulimia nervosa has fueled

202 (12-41) decreased frustration stress-induced binge eating in rats with a history of food restriction.

203 No episodes of binge eating in the aspiration therapy group or serious

204 regression analysis showed that the rate of binge eating in the d-fenfluramine group fell three time

205 The median frequency of binge eating in the previous 28 days declined from 22 to

206 Binge eating increased slightly through follow-up but re

207 t pills, laxatives, or diuretics, engaged in binge eating, induced vomiting, or exercised excessively

208 Binge eating is a highly heritable trait associated with

209 Binge eating is associated with obesity and has been con

210 The authors tested the hypothesis that binge eating is mediated by changes in opioid control of

211 marijuana and other drug use, we found that binge eating is uniquely predictive of incident overweig

212 nd although butorphanol did not trigger chow binge eating, it enhanced binge eating of palatable food

213 lso showed flexibility in foraging patterns, binge-eating less and using feeders more when they exper

214 The binge eating model was characterized by four temporally

215 We developed recently a binge-eating model in which female rats with a history o

216 e opioid system and food-related behavior in binge-eating obese individuals, these results support a

217 antagonist GSK1521498 on eating behaviour in binge-eating obese subjects.

218 ricted mice showed a significant increase in binge eating of a palatable high-fat food during stress

219 testing the ability of butorphanol to elicit binge eating of chow when palatable food was absent.

220 Compulsive, binge eating of highly palatable food constitutes a core

221 d not trigger chow binge eating, it enhanced binge eating of palatable food.

222 %, however, continued to engage in recurrent binge eating or purging behaviors (incidence rate, 0.026

223 Infrequent binge eating or purging or overeating without a loss of

224 rom bulimia nervosa (they had no episodes of binge eating or purging, were at normal weight, and had

225 weight and regular menstrual cycles, without binge eating or purging.

226 ation of food intake without the presence of binge-eating or purging behavior.

227 rts to integrate these models by focusing on binge eating phenotypes as the subgroup of obese individ

228 drink frequently, while both overeating and binge eating predicted starting to use marijuana and oth

229 mpulsive behaviours included hypersexuality, binge eating, punding, compulsive use of dopamine replac

230 han half crossed between the restricting and binge eating/purging anorexia nervosa subtypes over time

231 The binge eating/purging group showed significantly greater

232 (i.e., bulimia nervosa or anorexia nervosa, binge eating/purging type);14 with anorexia nervosa, res

233 Binge-eating recovery rates were equivalent for CBT and

234 Binge eating, recurrent and persistent episodes of overe

235 Risk of binge-eating relapse over 6 months was lower in particip

236 eating days/week from baseline and improving binge eating-related key secondary endpoints.

237 GAs (MD, -3.84 [CI, -6.55 to -1.13]) reduced binge-eating-related obsessions and compulsions, and SGA

238 etrograde endocannabinoid signaling, whereas binge eating resulted in the downregulation of a gene se

239 lts with body mass index >/= 30 kg m(-2) and binge eating scale scores >/= 19 received 1-week single-

240 acebo in its effects on weight, fat mass and binge eating scores.

241 r monetary incentives linked alcohol use and binge eating severity.

242 x correlated negatively with alcohol use and binge eating severity.

243 including the percentage of abstinence from binge eating (sibutramine group: 58.7%; placebo group: 4

244 ed lower energy consumption at baseline, and binge-eating status was associated with greater energy c

245 ome to inform molecular mechanisms mediating binge eating susceptibility and establishment.

246 d obsessional processes that accompany human binge-eating syndromes is discussed.

247 nd CBTgsh resulted in greater remission from binge eating than BWL (P < .05; odds ratios: BWL vs CBTg

248 ic food cravings, compulsive overeating, and binge eating that may represent a phenotype of obesity.

249 in the R + S rats with naloxone suppressing binge eating to control levels, and although butorphanol

250 reward characterizes disorders ranging from binge eating to drug addiction.

251 on a C57BL/6N background that showed reduced binge eating toward a wild-type C57BL/6J-like level.

252 Neither overeating nor binge eating was associated with starting to binge drink

253 arge cohort of adolescents and young adults, binge eating was more common among females than males.

254 ated the efficacy of sibutramine in reducing binge eating, weight, and associated psychopathology.

255 28, significantly more (P < 0.003) cases of binge eating were observed in MR participants than in th

256 tations, including starvation resistance and binge eating when food becomes available.

257 The authors developed an animal model of binge eating where history of caloric restriction with f

258 The neuronal substrate for binge eating, which can at times lead to obesity, is not

259 licated in reward-seeking behaviors, such as binge eating, which contributes to treatment resistance

260 Furthermore, compulsive food intake and binge eating will be considered from an evolutionary per

261 of longer duration, or by not eating, or by binge-eating without vomiting.

262 a rodent model to test whether a history of binge eating would augment subsequent responding for coc